MARLBOROUGH, Mass.,
July 7, 2014 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company
focused on discovering, developing and commercializing innovative
therapies addressing major unmet medical needs using RNA-targeted
technologies, today announced the appointment of Dr. Peter Campochiaro to its Scientific Advisory
Board. Campochiaro is the George S. and Dolores Dore Eccles
Professor of Ophthalmology and Neuroscience in the Johns Hopkins University School of Medicine. He is
a prominent researcher, clinician and educator in the field of
ophthalmology. He sees patients at the Wilmer Eye Institute at
Johns Hopkins.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
With more than 300 articles published in peer-reviewed medical
journals, Dr. Campochiaro is a clinician-scientist who does both
laboratory and clinical research. His major laboratory
interest is in elucidating the molecular pathogenesis of ocular
neovascularization and excessive vascular leakage. He has
generated many animal models of retinal and choroidal vascular
diseases that have been useful for evaluating drug and gene-based
therapies. His laboratory helped to demonstrate the importance of
vascular endothelial growth factor (VEGF) in retinal and choroidal
vascular diseases and his clinical trial group performed many of
the early phase studies evaluating VEGF antagonists. He
serves on Scientific Advisory Board of several pharmaceutical
companies.
"We are honored to have Dr. Campochiaro join our Scientific
Advisory Board," said Dr. Pamela
Pavco, Chief Development Officer of RXi Pharmaceuticals. "He
brings a wealth of clinical research experience in ophthalmology to
the Company that we will leverage to advance our ophthalmology
program."
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering, developing and
commercializing innovative therapies based on its proprietary,
self-delivering RNAi (sd-rxRNA®) platform. Therapeutics that use
RNA interference, or "RNAi," have great promise because of
their ability to down-regulate the expression of specific genes
that may be over-expressed in disease conditions. Building on the
pioneering work of scientific founder and Nobel Laureate Dr.
Craig Mello, a member of the RXi
Scientific Advisory Board, RXi's first RNAi product candidate,
RXI‑109, entered into human clinical trials in June 2012 and is currently being evaluated in
Phase 2 clinical trials to reduce dermal scarring (fibrosis).
RXI‑109 targets connective tissue growth factor (CTGF), which may
also be key in the development of retinal scarring. RXi's
sd‑rxRNA oligonucleotides are designed for therapeutic use and have
drug-like properties, such as high potency, target specificity,
serum stability, reduced immune response activation, and efficient
cellular uptake. These hybrid oligonucleotide molecules combine the
beneficial properties of conventional RNAi and antisense
technologies. This allows sd‑rxRNAs to achieve efficient
cellular uptake and potent, long-lasting intracellular activity.
For more information, please visit www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about future expectations, planned and future development of RXi
Pharmaceuticals Corporation's products and technologies.
Forward-looking statements about expectations and development plans
of RXi's products involve significant risks and
uncertainties: the risk that we may not be able to
successfully develop our candidates, or that development of
RNAi-based therapeutics may be delayed or not proceed as planned,
or that we may not develop any RNAi-based products; risks that the
development process for our product candidates may be delayed,
risks related to the development and commercialization of products
by our competitors, the risk related to our ability to control the
timing and terms of collaborations with third parties, and the
possibility that other companies or organizations may assert patent
rights preventing us from developing our products. Actual results
may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
SOURCE RXi Pharmaceuticals Corporation